Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma [News in Brief]

The addition of ipilimumab to nivolumab nudged up response rates and survival outcomes for patients—but with increased toxicity.

from Cancer via ola Kala on Inoreader http://ift.tt/2qYEkGQ
via IFTTT